Systemic chemotherapy is a standard treatment for patients with stage IV cancer with distant metastases, and there is little evidence of the effectiveness of local treatments for distant metastatic lesions. However, in recent years, randomized phase II trials targeting oligometastases in lung cancer and solid tumors have reported that local therapy combined with systemic chemotherapy improves clinical outcomes. We reviewed previous clinical trials and demonstrated the efficacy of radiotherapy for oligometastatic disease. Stereotactic body radiotherapy (SBRT) is a promising treatment that achieves high local control rates for oligometastatic disease. Although SBRT generally does not cause severe adverse events, the safety of SBRT combined with systemic chemotherapy needs to be carefully considered. We discussed the efficacy and safety of SBRT and summarized the details of SBRT methods and techniques for each metastatic site. Further research and clinical trials are warranted to improve the efficacy of SBRT combined with systemic chemotherapy for oligometastatic non-small cell lung cancer (NSCLC).
对于伴有远处转移的IV期癌症患者，全身化疗是标准治疗方案，目前关于局部治疗对远处转移病灶有效性的证据尚不充分。然而近年来，针对肺癌及实体瘤寡转移灶的随机II期临床试验表明，局部治疗联合全身化疗可改善临床预后。本文通过回顾既往临床试验，证实了放射治疗在寡转移疾病中的疗效。立体定向体部放疗（SBRT）作为一种前景广阔的治疗手段，在寡转移病灶中实现了较高的局部控制率。尽管SBRT通常不会引起严重不良事件，但其与全身化疗联合应用的安全性仍需审慎评估。本文系统探讨了SBRT的疗效与安全性，并针对不同转移部位总结了SBRT的具体方法和技术要点。未来需要进一步开展研究及临床试验，以提升SBRT联合全身化疗治疗寡转移性非小细胞肺癌（NSCLC）的疗效。
肿瘤(癌症)患者之家